Twitxy Saved

Viralgen

Verified account This account is verified. Learn more

@ViralgenVC

All-in on AAV gene therapy manufacturing that empowers innovators to bring more potential cures to more patients
Parque Tecnológico de Gipuzkoa viralgen.com Joined March 2020
213 Following 491 Followers 1.3K Posts

Latest posts 5

Viralgen Verified account @ViralgenVC
Some partnerships just make sense. Today we're proud to share that Viralgen is collaborating with #Gene2Cure Foundation, a nonprofit dedicated to advancing gene therapies for children with rare and ultra-rare genetic conditions.

Together, we'll be manufacturing a portfolio of investigational #AAV gene therapies using Aava™️, our proprietary platform.

As our CEO Jimmy Vanhove puts it: "Collaboration is central to advancing potential gene therapies for rare diseases." We couldn't agree more, and we're looking forward to working alongside the Gene2Cure team.

--> Read the full announcement here: viralgen.com/news/gene2cure…

#GeneTherapy #RareDisease #CDMO
Viralgen Verified account @ViralgenVC
Some news worth celebrating: Viralgen is now officially @GPTW_Spain Certified™️! 🎉

And the best part is who it comes from: our own team. The people who show up every day to help move promising gene therapies closer to patients, and who make this a place where ideas are shared, people look out for each other, and the science keeps moving forward.

(We're taking it as a great reason to celebrate, and an even better reason to keep going.)

Thank you to everyone at Viralgen for making it happen. Swipe through to see what our team had to say.

#GreatPlaceToWork #GPTWcertified #GeneTherapy #AAV #CDMO
Viralgen Verified account @ViralgenVC
The end of the year is always a time of transitions, and for Viralgen, it will come with a notable change. As a part of a planned succession, our CEO Jimmy Vanhove, will be leaving Viralgen after 4 years leading the company for a role within the broader Bayer Pharma network, leading the recently announced network development and expansion into the United States. In his new position, he will join Bayer’s Global Pharma Product Supply Leadership Team.

While we are sad to lose him to this new adventure, we are grateful for his years of leadership and wish him continued success in his new chapter. And we look forward to him reporting back on the other kind of football from just outside New Albany, Ohio.

At the same time, we are excited to announce his successor, Angela Ochoa, who will assume the role of Viralgen CEO as of January 1, 2027. She comes to us with almost 20 years experience in quality, manufacturing and strategy leadership.

At a time when Viralgen is expanding capacity and anticipating multiple commercial launches in the coming months, her leadership and expertise will be an exciting asset for our growth and continued evolution.

Welcome, Angela! Ongi etorri!

Read the full announcement: viralgen.com/news/viralgen-…
Viralgen Verified account @ViralgenVC
We’re looking forward to seeing you at #ESGCT this year. It’s unique opportunity to make the kinds of connections that drive the future of advanced therapies — including the ones you’re working on right now.

Viralgen will have a full team in booths F01 + F08, eager to hear about your development plans, and ready to reach out with ideas for improving the data, increasing the speed and reducing the risk of gene therapy manufacturing. All thanks to Aava™, our proven, high-performance platform.

The first step? We’d like to extend an invitation to meet up while you’re at ESGCT. Use the link below to pick a convenient time.

viralgen.com/esgct-2026

See you in Hamburg!

#ESGCTHamburg2026 #GeneTherapy #AAV #advancedtherapies
Viralgen Verified account @ViralgenVC
Viralgen is proud to announce a new collaboration with @EpilepsyGtx to support the development of EPY201, its lead gene therapy programme for focal refractory epilepsy.

Through this partnership, #Viralgen will bring its extensive AAV manufacturing expertise and proprietary AAVa™ platform to support the scalable, high-yield production of EPY201 as the programme advances toward first-in-human clinical trials, expected in the first half of 2027.

Focal refractory epilepsy remains an area of significant unmet need, and we are pleased to contribute our experience in AAV-based gene therapy manufacturing to help advance a potential new option for people living with this condition.

Read the full announcement: viralgen.com/news/epilepsyg…

#GeneTherapy #Epilepsy #AAV #FRE